The antibiotic Vabomere demonstrated statistical superiority over Zosyn, and could be a more attractive option than existing treatments for complicated urinary tract infections.
The Medicines Co. hopes the favorable efficacy and safety labeling that the US FDA approved for Vabomere will help the novel antibiotic break into the hospital market for complicated urinary tract infections (cUTI) – and help alleviate the company's financial woes.
Intravenous Vabomere combines a novel beta-lactamase inhibitor (BLI), vaborbactam, with the penem antibiotic meropenem (Pfizer Inc.'s Merrem and generics)....
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
